Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis
- PMID: 19997594
- PMCID: PMC2781169
- DOI: 10.1371/journal.pone.0008202
Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis
Abstract
Background: Dissociating glucocorticoid receptor (GR) ligands hold great promise for treating inflammatory disorders since it is assumed that they exert beneficial activities mediated by transrepression but avoid adverse effects of GR action requiring transactivation. Here we challenged this paradigm by investigating 2-(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride (CpdA), a dissociating non-steroidal GR ligand, in the context of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).
Methodology/principal findings: CpdA inhibited pro-inflammatory mediators in myelin-specific T cells and fibroblasts in a GR-dependent manner while gene activation was abolished. However, it also induced massive apoptosis in various cell types even in the absence of the GR by engaging a Bcl-2- and caspase-dependent pathway. (1)H NMR spectroscopy corroborated these findings by revealing that CpdA dissolved in buffered solutions rapidly decomposes into aziridine intermediates known to act as alkylating pro-apoptotic agents. Importantly, the dichotomy of CpdA action also became evident in vivo. Administration of high-dose CpdA to mice was lethal while treatment of EAE with low to intermediate amounts of CpdA dissolved in water significantly ameliorated the disease. The beneficial effect of CpdA required expression of the GR in T cells and was achieved by down regulating LFA-1 and CD44 on peripheral Th cells and by repressing IL-17 production.
Conclusions/significance: CpdA has significant therapeutic potential although adverse effects severely compromise its application in vivo. Hence, non-steroidal GR ligands require careful analysis prior to their translation into new therapeutic concepts.
Conflict of interest statement
Figures






Similar articles
-
Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis.Mol Endocrinol. 2010 Feb;24(2):310-22. doi: 10.1210/me.2009-0236. Epub 2009 Dec 4. Mol Endocrinol. 2010. PMID: 19965930 Free PMC article.
-
Compound A, a dissociated glucocorticoid receptor modulator, inhibits T-bet (Th1) and induces GATA-3 (Th2) activity in immune cells.PLoS One. 2012;7(4):e35155. doi: 10.1371/journal.pone.0035155. Epub 2012 Apr 9. PLoS One. 2012. PMID: 22496903 Free PMC article.
-
Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression.Mol Endocrinol. 2015 Oct;29(10):1486-97. doi: 10.1210/me.2015-1128. Epub 2015 Aug 31. Mol Endocrinol. 2015. PMID: 26322830 Free PMC article.
-
Discovery of Compound A--a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity.Oncotarget. 2015 Oct 13;6(31):30730-44. doi: 10.18632/oncotarget.5078. Oncotarget. 2015. PMID: 26436695 Free PMC article. Review.
-
Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy.Crit Rev Immunol. 2009;29(3):255-73. doi: 10.1615/critrevimmunol.v29.i3.50. Crit Rev Immunol. 2009. PMID: 19538138 Review.
Cited by
-
Effect of the plant derivative Compound A on the production of corticosteroid-resistant chemokines in airway smooth muscle cells.Am J Respir Cell Mol Biol. 2015 Nov;53(5):728-37. doi: 10.1165/rcmb.2014-0477OC. Am J Respir Cell Mol Biol. 2015. PMID: 25897650 Free PMC article.
-
Deletion of the Mineralocorticoid Receptor in Myeloid Cells Attenuates Central Nervous System Autoimmunity.Front Immunol. 2017 Oct 13;8:1319. doi: 10.3389/fimmu.2017.01319. eCollection 2017. Front Immunol. 2017. PMID: 29081780 Free PMC article.
-
T Cell Energy Metabolism Is a Target of Glucocorticoids in Mice, Healthy Humans, and MS Patients.Cells. 2023 Jan 30;12(3):450. doi: 10.3390/cells12030450. Cells. 2023. PMID: 36766792 Free PMC article.
-
In Vivo and In Vitro Evidence for an Interplay between the Glucocorticoid Receptor and the Vitamin D Receptor Signaling.Cells. 2023 Sep 15;12(18):2291. doi: 10.3390/cells12182291. Cells. 2023. PMID: 37759513 Free PMC article.
-
Novel Drug Delivery Systems Tailored for Improved Administration of Glucocorticoids.Int J Mol Sci. 2017 Aug 24;18(9):1836. doi: 10.3390/ijms18091836. Int J Mol Sci. 2017. PMID: 28837059 Free PMC article. Review.
References
-
- Lühder F, Reichardt HM. Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy. Crit Rev Immunol. 2009;29:255–273. - PubMed
-
- Kirwan J, Power L. Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis. Curr Opin Rheumatol. 2007;19:233–237. - PubMed
-
- Kleiman A, Tuckermann JP. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol. 2007;275:98–108. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous